Could a Stress-Boosting drug make immunotherapy work for Hard-to-Treat colorectal cancer?

This phase 1 trial tests a new two-drug combination for people with metastatic colorectal cancer that is microsatellite stable (MSS), a type that typically does not respond to immunotherapy alone. The study combines LB-100, which blocks a protein called PP2A to increase stress signals in cancer cells, with atezolizumab (Tecentriq), an immunotherapy that helps the immune system attack tumors. The goal is to find the best dose of LB-100 and see if the combination is safe and can shrink tumors in about 37 participants whose cancer has worsened after standard treatments.